Trends in the use of antiasthmatic medications in Morocco (1999–2010)

Abstract

BackgroundAsthma is a big public health problem in Morocco. The drug therapy existing in Morocco is currently insufficient because of the low purchasing power and the low health insurance coverage available to the average citizen in Morocco. In this study we evaluated the consumption of antiasthmatics in Morocco during the period 1999–2010, the classes of used drugs and the generics’ market share.MethodsWe used sales data from the Moroccan subsidiaries of the IMS Health “Intercontinental Marketing Service”. The consumption volume was converted to Defined Daily Doses (DDDs).ResultsDuring 1999–2010, antiasthmatics’s consumption increased from 3.91 to 14.47 DDD per 1000 inhabitants per day. In 2010, the association Beta-2-mimetic-Glucocorticosteroids were the most consumed (8.53 DDD/1000 Inhabitants/day) followed by the short-acting inhaled Beta-2-mimetic (4 DDD/1000 Inhabitants/day) and inhaled Glucocorticosteroids alone accounted for 1.13 DDD/1000 Inhabitants/day. The largest consumption share in volume was held by the short-acting inhaled Beta-2-mimetic (42%) followed by the combination Beta-2-mimetic-Glucocorticosteroids (38%). Between 1999 and 2010, the market for generic antiasthmatics increased from 1.84 to 2.18 DDD/1000 Inhabitants/day. The ratio of the monthly average cost of treatment to the minimum wage in Morocco decreased from 10.8% in 1999 to 7.11% in 2010.ConclusionAntiasthmatics’ consumption in Morocco has undergone significant changes between 1999 and 2010. However, the availability of these drugs expressed as the Average Monthly Expenditure/Guaranteed Minimum Wage ratio improved. Despite this, the use of antiasmathics in Morocco remains low.

Factors associated with asthma control: MOSAR study (Multicenter Observational Study of Asthma in Rabat-Morocco)

“…Asthma management remains unsteadily at the national plan compared to other countries [ 15 , 60 ]. The reasons for the inadequate quality of treatment is due to the combination of two factors; firstly the socioeconomic environment very particular developing countries with its outcomes: low purchasing power, inadequate health insurance and on the other hand the difficulties inherent in asthma patients: influence beliefs, poor adherence ..., and other extenuating factors.…”

“…The study about the evaluation of anti-asthmatic drugs consumption in Morroco [ 15 ] demonstrated that despite its high prevalence [ 3 ], the therapeutic care of asthma remains unsatisfactory at the national level compared to other countries, probably due to a combination of factors; the very particular socioeconomic environment of the developing countries with its corollaries (low purchasing power ...); the part of the generic drug and the insubstantial health insurance which is poorly distributed; in addition to the inherent difficulties to asthmatic patients (influence beliefs) and the absence of national recommendations about asthma care.…”

The availability, cost, and affordability of essential medicines for asthma and COPD in low-income and middle-income countries: a systematic review

“…Seven publications focused on pharmacy databases. 29,30,33,35,47,48,50 Two studies used surveys of healthcare professionals. 22,23 Two reports from Jordan and Sudan were not formally peer reviewed as they were government briefing documents from Médecins Sans Frontières.…”

Factors influencing anti-asthmatic generic drug consumption in Morocco: 1999-2010

“…It was not the case for salbutamol, which is prescribed, according to GINA, as a treatment for asthma attacks (Global Initiative for Asthma GINA 2011 ). In 2006, salbutamol represented 50.44% of anti-asthmatic consumption in Morocco (Ghanname et al 2012 ). In the United Kingdom it was 58% and in Spain 51%.…”